Curve Biosciences ·30 October 2025·3 outlets
Curve Biosciences raised $40 million for blood tests that monitor chronic disease
Curve Biosciences raised $40 million to take liquid biopsy beyond cancer and into chronic disease. The Stanford spin-out reads DNA methylation patterns in cell-free blood DNA and maps them back to the organ they came from, so one blood draw can track the progression of a liver condition such as MASH or cirrhosis without a biopsy or a scan.
We backed Curve because the science that made early cancer detection possible can now monitor the far larger population living with chronic disease, and Curve has built one of the most detailed tissue methylation atlases to do it. The founding team carries deep experience from Natera and GRAIL, where they helped build the blood tests that defined the category. Chronic disease monitoring is a vast market with poor existing tools, and the timing fits a broad move toward earlier, less invasive care.
- Company
- Curve Biosciences, www.curvebio.com
- First reported
- 30 October 2025
- Outlets
- Dallas Innovates, Inside Precision Medicine, BioSpace
Who covered it
- Dallas' Curve Biosciences Raises $40M for Its 'Whole-Body Intelligence' Disease Monitoring PlatformDallas Innovates, 12 November 2025
- Curve Biosciences Raises $40M for Blood-Based Chronic Disease MonitoringInside Precision Medicine, 30 October 2025
- Curve Biosciences Raises $40 Million to Bring Whole-Body Intelligence to Chronic Disease MonitoringBioSpace, 30 October 2025
Headlines and links belong to the publications that wrote them. Everything above this line is ours.